The stock of Concordia International Corp (NASDAQ:CXRX) is a huge mover today! About 526,378 shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 92.42% since April 22, 2016 and is downtrending. It has underperformed by 97.83% the S&P500.
The move comes after 7 months positive chart setup for the $125.50M company. It was reported on Nov, 25 by Barchart.com. We have $2.81 PT which if reached, will make NASDAQ:CXRX worth $8.79 million more.
Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on March, 22. They expect $-0.03 earnings per share, down 102.78% or $1.11 from last year’s $1.08 per share. After $-0.33 actual earnings per share reported by Concordia International Corp for the previous quarter, Wall Street now forecasts -90.91% EPS growth.
Concordia International Corp (NASDAQ:CXRX) Ratings Coverage
Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The rating was upgraded by Scotia Capital to “Sector Perform” on Monday, September 19. Goldman Sachs initiated the shares of CXRX in a report on Monday, June 6 with “Neutral” rating. The rating was initiated by IBC on Monday, November 30 with “Sector Perform”. The stock of Concordia International Corp (NASDAQ:CXRX) earned “Buy” rating by S&P Research on Friday, October 16. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, October 1. The rating was downgraded by GMP Securities on Monday, August 15 to “Hold”. The stock of Concordia International Corp (NASDAQ:CXRX) earned “Neutral” rating by Goldman Sachs on Monday, August 15. On Tuesday, August 11 the stock rating was maintained by Canaccord Genuity with “Buy”. TD Securities downgraded the shares of CXRX in a report on Thursday, August 4 to “Hold” rating. On Friday, October 16 the stock rating was maintained by Scotia Capital with “Sector Outperform”.
According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”
More news for Concordia International Corp (NASDAQ:CXRX) were recently published by: Prnewswire.com, which released: “Concordia International Corp. Announces CEO Transition Plan” on October 21, 2016. Prnewswire.com‘s article titled: “Shareholder Class Action Filed Against Concordia International Corp. – CXRX” and published on August 17, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.